Point72 Hong Kong’s Akebia Therapeutics AKBA Stock Holding History

Point72 Hong Kong’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-13,106	Closed	-$30K	–	1793
2021 Q4	$30K	Buy	+13,106	New	+$35.7K	﹤0.01%	1470
2021 Q3	–	Sell	-18,451	Closed	-$70K	–	1933
2021 Q2	$70K	Buy	18,451 +16,966	+1,142%	+$57.1K	﹤0.01%	1398
2021 Q1	$5K	Sell	1,485 -3,755	-72%	-$13.5K	﹤0.01%	1647
2020 Q4	$15K	Buy	5,240 +3,735	+248%	+$10.9K	﹤0.01%	1472
2020 Q3	$4K	Buy	+1,505	New	+$13.2K	﹤0.01%	1069
2020 Q2	–	Sell	-2,009	Closed	-$15K	–	1120
2020 Q1	$15K	Buy	2,009 +969	+93%	+$7.54K	0.01%	606
2019 Q4	$7K	Buy	1,040 +894	+612%	+$4.25K	﹤0.01%	1011
2019 Q3	$1K	Sell	146 -2,640	-95%	-$11.3K	﹤0.01%	888
2019 Q2	$13K	Buy	+2,786	New	+$15.8K	﹤0.01%	832
2018 Q3	–	Sell	-466	Closed	-$5K	–	863
2018 Q2	$5K	Sell	466 -4,383	-90%	-$43.9K	﹤0.01%	703
2018 Q1	$46K	Buy	+4,849	New	+$67.8K	0.02%	468
2017 Q3	–	Sell	-3,828	Closed	-$55K	–	776
2017 Q2	$55K	Buy	+3,828	New	+$48.5K	0.06%	207

Other funds holding AKBA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AIM

Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

OCM

Orchard Capital Management Chicago, Illinois $95.9M AUM 45.49% 1-Year Est. Return

Point72 Hong Kong's AKBA Position: Q1 2022 in Review

Point72 Hong Kong sold out of Akebia Therapeutics (AKBA) in Q1 2022, closing a stake of 13,106 shares — an estimated $30K sold.

Point72 Hong Kong first reported a position in AKBA in Q2 2017 and held it in 12 quarters. The position peaked at $70K in Q2 2021. 124 funds tracked by Wall St. Rank hold AKBA as of Q1 2022.

Point72 Hong Kong reported no remaining Akebia Therapeutics position as of Q1 2022 after selling out during the quarter.
Point72 Hong Kong sold 13,106 Akebia Therapeutics shares in Q1 2022, an estimated $30K.
Point72 Hong Kong first reported a position in Akebia Therapeutics in Q2 2017 and held it in 12 quarters.
Point72 Hong Kong's Akebia Therapeutics position peaked at $70K in Q2 2021.
124 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2022.

Based on Point72 Hong Kong's 13F filing for Q1 2022, filed 16 May 2022.